Glatiramer Acetate for MS Appears Safe Throughout Pregnancy Glatiramer Acetate for MS Appears Safe Throughout Pregnancy
In a study of 216 pregnancy cases, the rate of congenital disorders in newborns exposed to GA was not significantly different from those in US and European population databases.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 9, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Mylan nudges full-year guidance higher on generic Copaxone gains
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 6, 2017 Category: Pharmaceuticals Source Type: news
Teva warns on profit as drugmaker's problems deepen
JERUSALEM (Reuters) - Teva Pharmaceutical Industries, the world's biggest generic medicine maker, said it would miss 2017 profit forecasts due to competition in the U.S. market and weakening sales of its multiple sclerosis drug Copaxone, hammering its shares (Source: Reuters: Health)
Source: Reuters: Health - November 2, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
NeuroBreak: First Copaxone Generic Okayed; Plus for Pain Tx
(MedPage Today) -- News and commentary from the world of neurology and neuroscience (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - October 10, 2017 Category: Psychiatry Source Type: news
Synthon ’s generic version of Copaxone at 40mg receives European approval to treat MS
Netherlands-based pharmaceutical company Synthon ’s 40mg/ml of glatiramer acetate has received regulatory approval for the treatment of relapsing forms of multiple sclerosis (MS) in Europe. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 5, 2017 Category: Pharmaceuticals Source Type: news
Teva's Copaxone faces generic competition in Europe after U.S. hit
LONDON (Reuters) - Teva's blockbuster multiple sclerosis treatment Copaxone will face additional generic competition in Europe, just two days after Mylan NV won U.S. approval to sell cheaper versions of the medicine in the world's largest market. (Source: Reuters: Health)
Source: Reuters: Health - October 5, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Teva's Copaxone faces more generic competition in Europe
LONDON (Reuters) - Teva's blockbuster multiple sclerosis treatment Copaxone faces more generic competition in Europe, just two days after regulators approved cut-price copies of the medicine in the United States. (Source: Reuters: Health)
Source: Reuters: Health - October 5, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
With approval of generic MS drug, Mylan stock surges
With the approval from the U.S. Food and Drug Administration of a generic injection to treat multiple sclerosis, Mylan's shares rose 18 percent Wednesday afternoon.
Mylan (NASDAQ: MYL), which is based in The Netherlands but run out of its corporate offices in Cannonsburg, received approval late Tuesday for its Glatiramer Acetate injection. The drug was approved by the government agency as a suitable generic version of Teva's (NYSE:TEVA) Copaxone to treat pati ents with relapsing forms of MS, according… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 4, 2017 Category: Pharmaceuticals Authors: Stacey Federoff Source Type: news
Mylan surges, Teva slumps after FDA approves Copaxone copy
(Reuters) - Mylan NV's long-awaited U.S. approval for its generic version of rival Teva's blockbuster multiple sclerosis treatment Copaxone drove Mylan's shares up around 18 percent on Wednesday while Teva shares plunged. (Source: Reuters: Health)
Source: Reuters: Health - October 4, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Teva shares down 13% following FDA approval of generic Copaxone
Teva Pharmaceutical Industries Ltd.' stock price was trading down 13 percent Wednesday morning after the Food and Drug Administration granted marketing approval to a generic version of Teva ’s multiple sclerosis drug Copaxone.
The generic drug was developed by Mylan of Canonsburg.
Following the approval, Teva issued a statement saying any launch by Mylan of a generic version of Copaxone prior to final resolution of the pending patent appeals and other patent litigation “should be considered… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 4, 2017 Category: Biotechnology Authors: John George Source Type: news
Mylan surges, Teva slumps after FDA okays Copaxone copy
(Reuters) - Shares in Mylan jumped 16 percent in premarket trading on Wednesday after the U.S. Food and Drug Administration approved the drugmaker's generic version of Teva blockbuster multiple sclerosis drug Copaxone. (Source: Reuters: Health)
Source: Reuters: Health - October 4, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Mylan surges as its generic of Teva's Copaxone gets FDA nod
(Reuters) - Shares of Mylan NV jumped about 17 percent in premarket trading on Wednesday after the U.S. Food and Drug Administration approved the drugmaker's copycat version of Teva Pharmaceutical Industries Ltd's blockbuster multiple sclerosis drug. (Source: Reuters: Health)
Source: Reuters: Health - October 4, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Mylan says FDA approves its generic multiple sclerosis treatment
(Reuters) - Mylan NV said the U.S. Food and Drug Administration has approved two doses of its generic version of Teva's Copaxone used to treat patients with relapsing forms of multiple sclerosis. (Source: Reuters: Health)
Source: Reuters: Health - October 4, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Mylan revises earnings guidance, defers product launches to 2018
Mylan NV on Wednesday said it is deferring all major U.S. launches from its full-year 2017 financial guidance to 2018, citing ongoing challenges and the uncertain U.S. regulatory environment.
As a result, the pharmaceutical giant expects to deliver total revenues ranging between $11.5 billion and $12.5 billion and adjusted earnigns per share between $4.30 and $4.70. The product launches include generic versions of Advair and Copaxone. Mylan (Nasdaq:MYL) included the announcement in its quarterly… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 9, 2017 Category: Pharmaceuticals Authors: Patty Tascarella Source Type: news
Glatopa (glatiramer acetate Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 19, 2017 Category: Drugs & Pharmacology Source Type: news
